Cochrane · systematic review · CD004239
Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery
Wingert, AM, Liu, S-H, Lin, JC, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
7
No studies
11
Included studies
NR
No studies 11 · 61.1%Ungraded 0 · 0%Very low 7 · 38.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
NSAID versus placebo or active control in acute cystoid macular edema
Population: participants with acute CME (< 4 months) following cataract surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Visual improvement at end of treatment, as defined by two or more Snellen lines NSAID vs placebo or active control | RR 2 [0.46, 8.76] | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Persistence of visual improvement one month after discontinuation of treatment NSAID vs placebo or active control | no estimate extracted | NR | No studies |
Improvement in leakage on FFA Â NSAID vs placebo or active control | RR 1.11 [0.45, 2.75] | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Improvement in central macular thickness on OCT NSAID vs placebo or active control | no estimate extracted | NR | No studies |
Improved contrast sensitivity  NSAID vs placebo or active control | RR 1.11 [0.45, 2.75] | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Change in QoL NSAID vs placebo or active control | no estimate extracted | NR | No studies |
NSAID versus placebo in chronic cystoid macular edema
Population: participants with chronic CME (≥ 4 months) following cataract surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Visual improvement at end of treatment, as defined by two or more Snellen lines  NSAID vs placebo | RR 0.72 [0.3, 1.73] | 2 studies · 34 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Persistence of visual improvement one month after discontinuation of treatment NSAID vs placebo | RR 1.17 [0.44, 3.07] | 2 studies · 46 participants | Very low Downgraded: risk of bias, imprecision |
Improvement in leakage on FFA Â NSAID vs placebo | RR 1.93 [0.62, 6.02] | 2 studies · 40 participants | Very low Downgraded: risk of bias, imprecision |
Improvement in central macular thickness on OCT NSAID vs placebo | no estimate extracted | NR | No studies |
Improved contrast sensitivity NSAID vs placebo | no estimate extracted | NR | No studies |
Change in QoL NSAID vs placebo | no estimate extracted | NR | No studies |
NSAID versus active control in mixed cystoid macular edema
Population: participants with acute or chronic CME following cataract surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Visual improvement at end of treatment, as defined by two or more Snellen lines NSAID vs active control | RR 1.4 [1.02, 1.94] | 1 study · 68 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Persistence of visual improvement one month after discontinuation of treatment NSAID vs active control | no estimate extracted | NR | No studies |
Improvement in leakage on FFA NSAID vs active control | no estimate extracted | NR | No studies |
Improvement in central macular thickness on OCT NSAID vs active control | no estimate extracted | NR | No studies |
Improved contrast sensitivity NSAID vs active control | no estimate extracted | NR | No studies |
Change in QoL NSAID vs active control | no estimate extracted | NR | No studies |